Peptide Companion
Peptide Companion
blend
Recovery & Repair
Vial: 10 mg

How is BPC-157 + TB-500 (10 mg Blend) dosed and mixed?

BPC-157 + TB-500 (10 mg Blend) is a peptide blend research reference in the Recovery & Repair category for a 10 mg vial. The reference mixing guide adds 3 mL of bacteriostatic water, giving a concentration of 3.33 mg/mL. The published research schedule lists BPC daily, TB-500 twice weekly over 6–8 weeks; it is reference information, not a recommendation.

By Vincent Ceniceros · Published · Last updated

This blend combines two well-studied regenerative peptides: BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from human gastric juice with cytoprotective and wound-repair properties, and TB-500 (Thymosin Beta-4 fragment), a 43-amino-acid peptide involved in tissue repair, cell migration, and angiogenesis. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Dose
As per individual components
Frequency
BPC daily, TB-500 twice weekly
Timing
BPC morning/evening, TB-500 any time
Duration
6–8 weeks

Synergistic repair effects. Pre-mixed for convenience. Addresses both vascular and cellular repair.

Dosing Schedule
Phase / WeekDaily Dose (Total Blend)Each Peptide (mcg)Units (mL)
Weeks 1–2 (Initial)600 mcg300 mcg BPC + 300 mcg TB-50018 units (0.18 mL)
Weeks 3–4 (Loading)800 mcg400 mcg BPC + 400 mcg TB-50024 units (0.24 mL)
Weeks 5–8 (Maintenance)600 mcg300 mcg BPC + 300 mcg TB-50018 units (0.18 mL)
Mixing & Quick Reference
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
  • •Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL total concentration (1.67 mg/mL of each peptide).
  • •Typical daily range: 600–1000 mcg total blend once daily (provides 300–500 mcg of each peptide).
  • •Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg total blend on a U-100 insulin syringe.
  • •Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Supplies Needed
  • •Peptide Vials (BPC-157 + TB-500, 10 mg blend each):
  • •Insulin Syringes (U-100):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Benefits
  • •May support accelerated repair of tendons, ligaments, muscles, and soft tissue injuries.
  • •Preclinical evidence suggests gastroprotective and anti-inflammatory properties for BPC-157.
  • •TB-500 promotes wound repair and may reduce scarring through enhanced cell migration.
  • •Both peptides are generally well tolerated; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
  • •No significant toxicity has been documented up to high doses in animal studies.
How It Works

BPC-157 is a stable pentadecapeptide that promotes angiogenesis, modulates nitric oxide pathways, and demonstrates broad cytoprotective effects across gastrointestinal, musculoskeletal, and neurological tissues in preclinical models. It has shown activity at very low doses (nanogram to microgram per kilogram) without demonstrable toxicity in animal studies.

TB-500 (Thymosin Beta-4) is an actin-sequestering peptide that promotes cell migration, wound repair, and anti-inflammatory responses. It is well-tolerated in animal and early clinical studies, even at multi-milligram doses.

Combining these peptides may provide complementary mechanisms for tissue repair: BPC-157 for its trophic and anti-inflammatory effects, and TB-500 for enhanced cell migration and angiogenesis.

References and original studies

  • PubMed

    Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds

    View original study

  • Current Pharmaceutical Design (PubMed)

    Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract

    View original study

  • PMC

    Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies

    View original study

  • Annals of the New York Academy of Sciences (PubMed)

    Thymosin beta 4 and wound healing: new ideas

    View original study

  • PMC

    Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review

    View original study

  • Johns Hopkins Arthritis Center

    How to give a subcutaneous injection

    View source

  • PMC

    Subcutaneous drug delivery review: pharmacologic considerations

    View original study

  • ASIPP / Alternative Therapies in Health and Medicine

    Intra-articular injection of BPC-157 for multiple types of knee pain

    View source

  • A4M

    Thymosin Beta-4 professional monograph

    View source

  • PubMed

    Detection of thymosin beta-4 and related peptides in sport drug testing

    View original study

  • Journal of Physiology and Pharmacology (PubMed)

    BPC-157 activity at very low doses without toxicity in animal studies

    View original study

  • Expert Opinion on Biological Therapy (PubMed)

    Thymosin beta-4 and its role in wound healing

    View original study

  • CDC

    Vaccine administration: subcutaneous route (angle/site; no aspiration)

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View original study

About the author

Vincent Ceniceros

Vincent Ceniceros created Peptide Companion and publishes its Dosage Library. Each guide summarizes a reference protocol and links to the studies and sources it draws on.

Published · Last updated

Related guides

Work out the mixing math for any vial with the peptide reconstitution calculator, or browse the full Dosage Library.

Educational content adapted from peptidedosages.com. Not medical advice.